This is a ready-to-use protocol for qualifying the process parameters that set lipid nanoparticle (LNP) quality: the particle-forming mixing step and the ethanol-removal, buffer-exchange step that follows it. It is not a stability or release protocol; it demonstrates that the manufacturing process reliably produces particles meeting the target critical quality attribute profile across the intended operating range. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your normal document control, review, and approval before execution. A filled specimen follows. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | LNP CPP Qualification Protocol for <<FILL: product / payload>> |
| Document number | <<FILL: e.g. LNP-CPP-2026-04>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Site | <<FILL>> |
| Linked formulation development plan | <<FILL: ref>> |
| Linked formulation stress risk assessment | <<FILL: ref>> |
| Protocol owner | <<FILL: e.g. Formulation Development Lead>> |
1. Purpose
This protocol defines the process parameters, acceptance criteria, and study design needed to demonstrate that the mixing and buffer-exchange steps used to manufacture <<FILL: product>> reliably produce lipid nanoparticles meeting the target critical quality attribute profile, across the range the commercial or clinical manufacturing process is intended to operate within.
2. Scope
| Dimension | Decision |
|---|---|
| Process steps in scope | Particle-forming mixing (microfluidic or T-junction) and post-mixing buffer exchange by tangential flow filtration |
| Product / payload | <<FILL: e.g. siRNA, mRNA>> |
| Scale | <<FILL: bench / pilot / commercial-representative>> |
| Out of scope | <<FILL: e.g. drug substance oligonucleotide synthesis, fill-finish, covered under their own protocols>> |
3. Responsibilities
| Role | Responsibility |
|---|---|
| Formulation development lead / author | Writes this protocol, oversees execution, compiles data |
| Process engineering | Operates the mixing and TFF equipment per the qualified parameter ranges below |
| Analytical development | Runs the CQA panel per validated or qualified methods and reports results |
| Quality Assurance | Reviews and approves the protocol, dispositions deviations, approves the report |
4. Prerequisites
Do not start execution until every prerequisite below is confirmed true, with evidence referenced.
| Prerequisite | Evidence ref |
|---|---|
| Lipid composition and target molar ratios locked from formulation development | <<FILL>> |
| Analytical methods for particle size, PDI, encapsulation efficiency, and zeta potential qualified or validated | <<FILL>> |
| Mixing equipment (microfluidic or T-junction system) installed and operationally qualified | <<FILL>> |
| TFF system and membrane installed, operationally qualified, and flushed per its own qualification | <<FILL>> |
| Raw materials (lipids, oligonucleotide drug substance) released and available | <<FILL>> |
5. Critical process parameters (CPPs)
| Parameter | Process step | Target | Acceptable range | Monitoring method |
|---|---|---|---|---|
| Flow rate ratio (aqueous : ethanol) | Mixing | <<FILL>> | <<FILL>> | In-line flow controller readout |
| Total flow rate | Mixing | <<FILL>> | <<FILL>> | In-line flow controller readout |
| Nitrogen-to-phosphate (N/P) ratio | Formulation / mixing | <<FILL>> | <<FILL>> | Calculated from lipid and oligonucleotide input quantities |
| Mixing inlet temperature | Mixing | <<FILL>> | <<FILL>> | In-line temperature probe |
| TFF transmembrane pressure | Buffer exchange | <<FILL>> | <<FILL>> | In-line pressure gauge |
| TFF diafiltration volume (number of exchanges) | Buffer exchange | <<FILL>> | <<FILL>> | Calculated from permeate volume collected |
| TFF process time / residence time | Buffer exchange | <<FILL>> | <<FILL>> | Elapsed process time log |
Every CPP range here traces to formulation development and small-scale screening data referenced in section 4; a range invented for this protocol with no upstream basis is not defensible.
6. Critical quality attributes (CQAs)
| Attribute | Test method | Acceptance criterion | Sampling stage |
|---|---|---|---|
| Particle size (Z-average) | Dynamic light scattering | <<FILL>> | In-process and final |
| Polydispersity index (PDI) | Dynamic light scattering | <<FILL>> | In-process and final |
| Encapsulation efficiency | Dye-exclusion assay (e.g. fluorescent nucleic acid dye, total vs. free signal) | <<FILL>> | Final |
| Zeta potential | Electrophoretic light scattering | <<FILL>> | Final |
| Payload identity and content | <<FILL: e.g. RP-IP-HPLC, RT-qPCR>> | <<FILL>> | Final |
| Functional potency | <<FILL: assay specific to mechanism, e.g. gene silencing activity>> | <<FILL>> | Final, or per stability plan |
7. Batch / run matrix
| Run | Purpose | Flow rate ratio | Total flow rate | N/P ratio | Planned date |
|---|---|---|---|---|---|
| LNP-CPP-1 | Center-point, demonstrate baseline performance | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| LNP-CPP-2 | Low edge of qualified range | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| LNP-CPP-3 | High edge of qualified range | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
State the rationale for the run count and the specific edges tested in section 2; a design that qualifies only the center point of the operating range makes no claim about the range’s actual edges.
8. Deviation handling
Any excursion outside a CPP range, any fail against a CQA acceptance criterion, or any departure from this protocol is recorded as a deviation per <<FILL: deviation SOP-ID>> at the point it is found. Each deviation states the affected parameter or attribute, root cause where determinable, and an impact assessment on the run’s fitness to support the qualification conclusion. Do not discard or repeat a run without a documented, QA-approved rationale.
9. Acceptance criteria for the qualification
Qualification succeeds only when every run in the matrix meets every CQA acceptance criterion in section 6, every CPP stayed within its target range or a deviation demonstrates the excursion did not affect particle quality, and no open deviation remains unresolved. A particle size or PDI result that passes while encapsulation efficiency fails is not eligible for a passing conclusion; the four CQA categories in section 6 are independent and all must pass.
10. Summary and conclusion
State, on completion: run-by-run results against every CPP and CQA, all deviations and their resolution, and an explicit conclusion on whether the qualified CPP ranges reliably produce particles meeting the target CQA profile across the tested range.
11. Attachments
<<FILL: raw DLS and encapsulation efficiency traces, TFF process logs, deviation records>>
12. References
ICH Q8(R2), Pharmaceutical Development. ICH Q9(R1), Quality Risk Management. FDA guidance, “Process Validation: General Principles and Practices” (January 2011).
Confirm the current version of each reference before issue.
13. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
14. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Formulation Development) | <<FILL>> | ||
| Reviewer (Process Engineering) | <<FILL>> | ||
| Reviewer (Analytical Development) | <<FILL>> | ||
| Approver (QA) | <<FILL>> |
Filled specimen
Extract for an example siRNA-LNP program, three-run CPP qualification at pilot scale. Product and numbers are illustrative.
| Field | Entry |
|---|---|
| Product | Acme Therapeutics, ATX-siR2, siRNA-LNP, hepatocyte target |
| Runs | LNP-CPP-1 at a 3:1 aqueous:ethanol flow rate ratio (center point), LNP-CPP-2 at 2:1 (low edge), LNP-CPP-3 at 4:1 (high edge), total flow rate and N/P ratio held constant across all three |
| Key CQA result | Particle size 68 to 74 nm and PDI below 0.15 across all three runs; encapsulation efficiency 92 to 96 percent across all three runs |
| Deviation | LNP-CPP-2 showed a transient TFF transmembrane pressure excursion above range for six minutes during the second diafiltration exchange, logged as DEV-2026-0142; particle size and encapsulation efficiency results bracketing the excursion remained within acceptance, so the deviation was closed with no impact on the CQA conclusion |
| Conclusion | The qualified flow rate ratio range of 2:1 to 4:1 reliably produces particles meeting the target CQA profile; the range is carried forward into the commercial process description |
The specimen shows what a reviewer checks for: both edges of the operating range actually tested, not just the center point, and a real deviation assessed against the specific CQA it could plausibly affect before the conclusion was written.
Common inspection findings this protocol prevents
- A CPP range asserted in a process description with no qualification run at either edge of the range, only at the center point.
- Particle size and PDI reported as the full CQA panel, with encapsulation efficiency or zeta potential omitted from the qualification.
- An encapsulation efficiency or particle size method used across the qualification runs with no evidence it was validated or qualified at this specific lipid composition and mixing condition.
- A TFF buffer-exchange parameter range never separately qualified, treated as a formality after the mixing step was qualified.
- A deviation during a qualification run closed with no stated impact assessment on the specific CQA it could plausibly affect.
How to adapt this protocol
- Set your document number, payload, site, and linked formulation development references in the header.
- Populate the CPP table in section 5 from your own small-scale screening data, not from a generic starting range.
- Design the run matrix in section 7 to bracket both edges of the range you intend to claim, not only the center point.
- Confirm every analytical method in section 6 is qualified or validated at the specific lipid composition and particle size range this program uses before relying on its results.
- Confirm every reference in section 12 against the current published version before issue.